T. Rowe Price Associates
IDYA icon

T. Rowe Price Associates’s IDEAYA Biosciences IDYA Stock Holding History

T. Rowe Price Associates’s Portfolio IDYA Stock Details IDYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$43.8M Sell
1,315,869
-133,276
-9% -$4.47M 0.01% 811
2025
Q4 		$50.1M Buy
1,449,145
+339,405
+31% +$10.8M 0.01% 821
2025
Q3 		$30.2M Sell
1,109,740
-795,176
-42% -$19.2M ﹤0.01% 950
2025
Q2 		$40M Sell
1,904,916
-1,570,706
-45% -$30.1M ﹤0.01% 786
2025
Q1 		$56.9M Sell
3,475,622
-391,286
-10% -$8.34M 0.01% 688
2024
Q4 		$99.4M Sell
3,866,908
-148,390
-4% -$4.2M 0.01% 566
2024
Q3 		$127M Buy
4,015,298
+271,557
+7% +$10.3M 0.01% 519
2024
Q2 		$131M Sell
3,743,741
-308,759
-8% -$12.2M 0.02% 486
2024
Q1 		$178M Buy
4,052,500
+486,222
+14% +$20.9M 0.02% 444
2023
Q4 		$127M Buy
3,566,278
+535,909
+18% +$16M 0.02% 501
2023
Q3 		$81.8M Buy
3,030,369
+527,696
+21% +$13.4M 0.01% 550
2023
Q2 		$58.8M Buy
2,502,673
+1,036,086
+71% +$21.3M 0.01% 656
2023
Q1 		$20.1M Sell
1,466,587
-196,941
-12% -$3.28M ﹤0.01% 919
2022
Q4 		$30.2M Sell
1,663,528
-195,349
-11% -$3.29M ﹤0.01% 807
2022
Q3 		$27.7M Sell
1,858,877
-27,375
-1% -$356K ﹤0.01% 814
2022
Q2 		$26M Sell
1,886,252
-228,741
-11% -$2.54M ﹤0.01% 1097
2022
Q1 		$23.7M Sell
2,114,993
-586,532
-22% -$8.65M ﹤0.01% 1192
2021
Q4 		$63.9M Buy
2,701,525
+365,619
+16% +$8.49M 0.01% 911
2021
Q3 		$59.5M Buy
2,335,906
+1,025,929
+78% +$24M 0.01% 950
2021
Q2 		$27.5M Buy
1,309,977
+409,712
+46% +$8.42M ﹤0.01% 1222
2021
Q1 		$21.2M Buy
900,265
+429,166
+91% +$8.29M ﹤0.01% 1263
2020
Q4 		$6.59M Buy
+471,099
New +$6.38M ﹤0.01% 1408

Other funds holding IDYA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

T. Rowe Price Associates's IDYA Position: Q1 2026 in Review

T. Rowe Price Associates reduced its IDEAYA Biosciences (IDYA) stake by 9.2% in Q1 2026, selling an estimated $4.47M and leaving 1,315,869 shares worth $43.8M. The position accounts for 0.01% of the portfolio, ranked #811.

T. Rowe Price Associates first reported a position in IDYA in Q4 2020 and has held it in 22 quarters since. The position peaked at $178M in Q1 2024. 253 funds tracked by Wall St. Rank hold IDYA as of Q1 2026.

  • T. Rowe Price Associates held 1,315,869 shares of IDEAYA Biosciences worth $43.8M as of Q1 2026.
  • T. Rowe Price Associates sold 133,276 IDEAYA Biosciences shares in Q1 2026, an estimated $4.47M.
  • IDEAYA Biosciences made up 0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #811 holding.
  • T. Rowe Price Associates first reported a position in IDEAYA Biosciences in Q4 2020 and has held it in 22 quarters since.
  • T. Rowe Price Associates's IDEAYA Biosciences position peaked at $178M in Q1 2024.
  • 253 funds tracked by Wall St. Rank held IDEAYA Biosciences as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.